Shadab A. Siddiqi

Dr. Shadab A. Siddiqi

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
STSamata Tiwari
Samata Tiwari
Shadab A. SiddiqiShadab A. Siddiqi
Shadab A. Siddiqi
Steady increase in the incidence of atherosclerosis is becoming a major concern not only in the United States but also in other countries. One of the major risk factors for the development of atherosclerosis is high concentrations of plasma low-density lipoprotein, which are metabolic products of very low-density lipoprotein (VLDL). VLDLs are synthesized and secreted by the liver. In this review, we discuss various stages through which VLDL particles go from their biogenesis to secretion in the circulatory system. Once VLDLs are synthesized in the lumen of the endoplasmic reticulum, they are transported to the Golgi. The transport of nascent VLDLs from the endoplasmic reticulum to Golgi is a complex multistep process, which is mediated by a specialized transport vesicle, the VLDL transport vesicle. The VLDL transport vesicle delivers VLDLs to the cis -Golgi lumen where nascent VLDLs undergo a number of essential modifications. The mature VLDL particles are then transported to the plasma membrane and secreted in the circulatory system. Understanding of molecular mechanisms and identification of factors regulating the complex intracellular VLDL trafficking will provide insight into the pathophysiology of various metabolic disorders associated with abnormal VLDL secretion and identify potential new therapeutic targets.

1 February 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
STSamata Tiwari
Samata Tiwari
SSShaila Siddiqi
Shaila Siddiqi
Shadab A. SiddiqiShadab A. Siddiqi
Shadab A. Siddiqi
Nascent very low density lipoprotein (VLDL) exits the endoplasmic reticulum (ER) in a specialized ER-derived vesicle, the VLDL transport vesicle (VTV). Similar to protein transport vesicles (PTVs), VTVs require coat complex II (COPII) proteins for their biogenesis from the ER membranes. Because the size of the VTV is large, we hypothesized that protein(s) in addition to COPII components might be required for VTV biogenesis. Our proteomic analysis, supported by Western blotting data, shows that a 26-kDa protein, CideB, is present in the VTV but not in other ER-derived vesicles such as PTV and pre-chylomicron transport vesicle. Western blotting and immunoelectron microscopy analyses suggest that CideB is concentrated in the VTV. Our co-immunoprecipitation data revealed that CideB specifically interacts with VLDL structural protein, apolipoprotein B100 (apoB100), but not with albumin, a PTV cargo protein. Confocal microscopic data indicate that CideB co-localizes with apoB100 in the ER. Additionally, CideB interacts with COPII components, Sar1 and Sec24. To investigate the role of CideB in VTV biogenesis, we performed an in vitro ER budding assay. We show that the blocking of CideB inhibits VTV budding, indicating a direct requirement of CideB in VTV formation. To confirm our findings, we knocked down CideB in primary hepatocytes and isolated ER and cytosol to examine whether they support VTV budding. Our data suggest that CideB knockdown significantly reduces VTV biogenesis. These findings suggest that CideB forms an intricate COPII coat and regulates the VTV biogenesis.

1 April 2012 in Journal of Proteomics
Verified
Journal Article
Closed access
ARAbdul Rahim
Abdul Rahim
ENErika Nafi-Valencia
Erika Nafi-Valencia
SSShaila Siddiqi
Shaila Siddiqi
RBRiyaz Basha
Riyaz Basha
CRChukwuemeka C. Runyon
Chukwuemeka C. Runyon
Shadab A. SiddiqiShadab A. Siddiqi
Shadab A. Siddiqi

14 March 2014 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
THTanvir Hossain
Tanvir Hossain
ARAladdin Riad
Aladdin Riad
SPSampath Parthasarathy
Sampath Parthasarathy
Shadab A. SiddiqiShadab A. Siddiqi
Shadab A. Siddiqi
Post-Golgi trafficking of mature VLDL (very-low-density lipoprotein) is crucial in maintaining normal TAG (triacylglycerol) homoeostasis of hepatocytes; however, the mechanism that regulates the exit of mature VLDL from the TGN (trans-Golgi network) is not known. We developed an in vitro TGN-budding assay that allowed us to examine the formation of secretory vesicles from the TGN in primary rat hepatocytes. We isolated TAG-rich PG-VTVs (post-TGN VLDL transport vesicles) using a continuous sucrose density gradient. PG-VTVs were distributed in low-density fractions, whereas protein transport vesicles were present in relatively higher-density fractions of the same sucrose gradient. EM revealed large intact PG-VTVs ranging 300–350 nm in size. The biogenesis of PG-VTVs from the TGN required cytosol, ATP, GTP hydrolysis and incubation at 37°C. PG-VTVs concentrated the VLDL proteins: apolipoproteins apoB100, apoAIV, apoAI and apoE, but did not contain either albumin or transferrin. Proteinase K treatment did not degrade VLDL core proteins, suggesting that PG-VTVs were sealed. PG-VTVs were able to fuse with and deliver VLDL to the PM (plasma membrane) in a vectorial manner. We conclude that we have identified a new TGN-derived vesicle, the PG-VTV, which specifically transports mature VLDL from the TGN to the PM.

1 June 2012 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
BSB. Sengupta
B. Sengupta
Shadab A. SiddiqiShadab A. Siddiqi
Shadab A. Siddiqi
The increasing incidence of hepatocellular carcinoma (HCC) is of great concern not only in the United States but throughout the world because of two major reasons: firstly, HCC is one of the most lethal form of malignancies with less than 10% survival rate and secondly, a lack of prudent diagnostics makes early detection of HCC nearly impossible. The poor prognosis of HCC accentuates the need to develop new diagnostic markers and therapeutic approaches. In this review we discuss recent advances made in the discovery of molecular biomarkers and their significance in the detection of HCC. We focus on three major classes of biomarkers: serological, tumor, peri-tumoral tissue and cancer stem cell markers. Considerable progress has been made recently in our understanding of HCC at the molecular level increasing the potential of molecular targeted therapy. A number of molecular targets have been identified that have been showing promising results. Of particular interest is Sorafenib, a multi-tyrosine kinase inhibitor that has been approved for the HCC treatment. Inhibitors of other molecular targets such as VEGF, EGFR, mTOR etc. are emerging as plausible therapeutic agents for the treatment of HCC and are discussed in this review.

1 February 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
STSimeon Thibeaux
Simeon Thibeaux
SSShaila Siddiqi
Shaila Siddiqi
OZOlga Zhelyabovska
Olga Zhelyabovska
FMFaisal Moinuddin
Faisal Moinuddin
MMMichal M. Masternak
Michal M. Masternak
Shadab A. SiddiqiShadab A. Siddiqi
Shadab A. Siddiqi
Synthesis and secretion of hepatic triglycerides (TAG) associated with very low-density lipoprotein (VLDL) play a major role in maintaining overall lipid homeostasis. This study aims to identify factors affecting synthesis and secretion of VLDL-TAG using the growth hormone-deficient Ames dwarf mouse model, which has reduced serum TAG. Proteomic analysis coupled with a bioinformatics driven approach revealed that these mice express greater amounts of hepatic cathepsin B and lower amounts of liver fatty acid binding protein (LFABP), than their wild type littermates. siRNA-mediated knockdown of cathepsin B in McA-RH7777 cells resulted in a 39% increase in [3H] TAG associated with VLDL secretion. Cathepsin B knockdown was accompanied by a 74% increase in cellular LFABP protein levels, but only when cells were exposed to 0.4 mM oleic acid (OA) complexed to bovine serum albumin (BSA). The cathepsin B knockdown and 24-hour treatment with OA resulted in increased CD36 expression alone and additively. Co-localization of LFABP and cathepsin B was observed in a distinct Golgi apparatus-like pattern, which required a 1-hour OA treatment. Moreover, we observed co-localization of LFABP and ApoB, independent of the OA treatment. Over-expression of cathepsin B resulted in decreased OA-uptake and VLDL secretion. Co-expression of cathepsin B and cathepsin B-resistant mutant LFABP in McA-RH7777 cells resulted in an increased TAG secretion as compared to cells co-expressing cathepsin B and wild-type LFABP. Together, these data indicate that cathepsin B regulates VLDL secretion and FFA uptake via cleavage of LFABP, which occurs in response to oleic acid exposure.